The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target - Cancer Cell International

Belgique Nouvelles Nouvelles

The emerging role of MicroRNA-182 in tumorigenesis; a promising therapeutic target - Cancer Cell International
Belgique Dernières Nouvelles,Belgique Actualités
  • 📰 BioMedCentral
  • ⏱ Reading Time:
  • 35 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 71%

A Review published in Cancer Cell International discusses the effects of miR-182 dysregulation on the signaling pathways involved in tumorigenesis and finds that miRNA- 182 can be a promising target in the treatment and diagnosis of various malignancies.

]. The improper expression of these enzymes has been confirmed in many cancers, including CRC. The expression level of ST6GALNAC2 as one of the STs is downregulated in CRC tissues and 5-FU-resistant CRC cell lines. Increased ST6GALNAC2 levels are associated with poor survival in CRC.

tumor suppressor. belongs to the Forkhead box O transcription factor family and plays an important role in the cell cycle. Studies indicated that miR-182 is involved in increasing the invasion, migration, and cell proliferation of prostate cancer by targeting and thus suppressing the translation of this mRNA []. Another study reported that three genes, FOXF2, RECK, and MTSS1, which act as tumor suppressors and are involved in inhibiting the development of prostate cancer cells by reducing invasion and migration, were targeted by miR-182-5p. It should be noted that RECK shows its tumor suppressor function by reducing the invasion of prostate cancer by inhibiting MMP-2.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

BioMedCentral /  🏆 22. in UK

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer - npj Breast CancerRAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer - npj Breast Cancernpj Breast Cancer - RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer
Lire la suite »

Student with sore back given weeks to live after heartbreaking cancer diagnosisStudent with sore back given weeks to live after heartbreaking cancer diagnosisDylan Lamb has been told he has weeks to live after his Leukaemia returned last month. The 20-year-old is now in need of a clinical trial in America that could save his life.
Lire la suite »

Film star Jake Abraham's warning after terminal cancer diagnosisFilm star Jake Abraham's warning after terminal cancer diagnosisHe was continuing to work despite not feeling well
Lire la suite »

Understanding the impact of HPV on the vaginal microbiome and its role in cervical cancerUnderstanding the impact of HPV on the vaginal microbiome and its role in cervical cancerUnderstanding the impact of HPV on the vaginal microbiome and its role in cervical cancer researchsquare microbiome HPV vaginalmicrobiome womenshealth health cancer cervicalcancer
Lire la suite »

Breast cancer and MEN1: exploring the connectionBreast cancer and MEN1: exploring the connectionBreast cancer and MEN1: exploring the connection PLOSONE UTAustin breastcancer MEN1 cancer womenshealth genomics mRNA
Lire la suite »

I hid cancer diagnosis as it was hard to talk about, admits Merlin GriffithsI hid cancer diagnosis as it was hard to talk about, admits Merlin GriffithsFIRST Dates star Merlin Griffiths has opened up about keeping his cancer diagnosis a secret. The 47-year-old First Dates star is living with bowel cancer and has undergone chemotherapy and two oper…
Lire la suite »



Render Time: 2025-04-20 19:14:29